Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 7/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.49 |
| ▸ | KCNN3 | Q9UGI6 | 4/20 | 0.48 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | CCR4 | P51679 | 1/20 | 0.44 |
| ▸ | KCNN1 | Q92952 | 1/20 | 0.43 |
| ▸ | KCNN2 | Q9H2S1 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13780222 | 0.87 | DPP4 (0.62) | DPP4EPHX2KCNN3CDK2CCR4 | |
| SCHEMBL13780276 | 0.81 | DPP4 (0.68) | DPP4EPHX2KCNN3CDK2CCR4 | |
| SCHEMBL4199130 | 0.81 | DPP4 (0.82) | DPP4KCNN3CDK2 | |
| SCHEMBL13780015 | 0.80 | CCR4 (0.64) | DPP4CCR4 | |
| SCHEMBL4209204 | 0.80 | CCR4 (0.64) | DPP4CCR4 | |
| SCHEMBL13780223 | 0.80 | DPP4 (0.60) | DPP4EPHX2KCNN3CDK2CCR4 | |
| SCHEMBL4218524 | 0.80 | DPP4 (0.47) | DPP4KCNN3CDK2CCR4ALDH1A1 | |
| SCHEMBL13780243 | 0.76 | DPP4 (0.66) | DPP4EPHX2KCNN3CCR4 | |
| SCHEMBL14844307 | 0.76 | DPP4 (0.61) | DPP4EPHX2KCNN3CDK2CCR4 | |
| SCHEMBL13780009 | 0.76 | DPP4 (0.57) | DPP4EPHX2CDK2CCR4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090182140-A1 | Alicyclic Heterocyclic Compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-07-16 | — | — | US | disclosed |
| US-20090182140-A1 | Alicyclic Heterocyclic Compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-07-16 | — | — | US | disclosed |
| US-20090182140-A1 | Alicyclic Heterocyclic Compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-07-16 | — | — | US | disclosed |
| EP-1970373-A1 | ALICYCLIC HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-09-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090182140-A1 | Alicyclic Heterocyclic Compound | CCR4, CCR1, HRH4 | DPP4 641/4885EPHX2 265/4885KCNN3 1892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.